Current Treatment Options in Oncology

, Volume 14, Issue 3, pp 337–349 | Cite as

Current Therapy and Future Directions in Biliary Tract Malignancies

Upper Gastrointestinal Cancers (JD Berlin, Section Editor)

Opinion Statement

Cancers of the biliary tree represent a rare group of diseases with a devastating impact on patients. Gallbladder cancer often is associated with cholelithiasis. Cholangiocarcinoma may arise in the setting of biliary inflammation, such as primary sclerosing cholangitis, but most commonly occurs in patients without a particular risk factor. Surgical removal of biliary cancer is essential for cure, but it is associated with a very high rate of recurrence and for many patients is not possible at the time of diagnosis. Although risk factors differ for each anatomic site, systemic treatment is generally similar. Various adjunctive therapies, such as radiation and embolization, have been investigated for biliary tract cancers with modest success and efforts are ongoing to understand how to optimize these tools. Retrospective series and pooled analysis suggest a benefit for adjuvant treatment following resection, but prospective data are limited. Ongoing and planned phase 3 trials should help to clarify the role of adjuvant chemotherapy and radiation. For advanced disease, chemotherapy improves quality of life and survival, and gemcitabine with cisplatin represents the standard of care. However, all patients ultimately progress on this therapy, so clinical trials of new and better agents are essential to expand the existing treatment options for patients.

Keywords

Biliary tract cancer Cholangiocarcinoma Gallbladder carcinoma Chemotherapy 

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: •Of importance. ••Of major importance

  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Shaib YH, Davila JA, McGlynn K, et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004;40(3):472–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Chapman RW. Risk factors for biliary tract carcinogenesis. Ann Oncol. 1999;10 Suppl 4:308–11.PubMedCrossRefGoogle Scholar
  4. 4.
    Shaib YH, El-Serag HB, Davila JA, et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case–control study. Gastroenterology. 2005;128(3):620–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.PubMedCrossRefGoogle Scholar
  6. 6.
    Hsing AW, Gao YT, Han TQ, et al. Gallstones and the risk of biliary tract cancer: a population-based study in China. Br J Cancer. 2007;97(11):1577–82.PubMedCrossRefGoogle Scholar
  7. 7.
    Randi G, Franceschi S, La Vecchia C. Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer. 2006;118(7):1591–602.PubMedCrossRefGoogle Scholar
  8. 8.
    Randi G, Malvezzi M, Levi F, et al. Epidemiology of biliary tract cancers: an update. Ann Oncol. 2009;20(1):146–59.PubMedCrossRefGoogle Scholar
  9. 9.
    Khan SA, Davidson BR, Golden RD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61(12):1657–69.PubMedCrossRefGoogle Scholar
  10. 10.
    Saini S. Imaging of the hepatobiliary tract. N Engl J Med. 1997;336:1889–94.PubMedCrossRefGoogle Scholar
  11. 11.
    Anderson CD, Rice MH, Pinson CW, et al. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg. 2004;8(1):90–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Sainani NI, Catalano OA, Holalkere NS, et al.: Cholangiocarcinoma: current and novel imaging techniques. Radiographics 28(5): 1263–1287. Google Scholar
  13. 13.
    De Jong MC, Nathan H, Sotiropoulos GC, et al. Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 2011;29(23):3140–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Klempnauer J, Ridder GJ, von Wasielewski R, et al. Resectional surgery of hilar cholangiocarcinoma: a multivariate analysis of prognostic factors. J Clin Oncol. 1997;15(3):947–54.PubMedGoogle Scholar
  15. 15.
    Jarnagin WR, Ruo L, Little SA, et al. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer. 2003;98(8):1689–700.PubMedCrossRefGoogle Scholar
  16. 16.
    Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effect than resection for hilar cholangiocarcinoma. Ann Surg. 2005;242(3):451–8.PubMedGoogle Scholar
  17. 17.
    Hari DM, Howard JH, Leung AM, et al. A 21-year analysis of stage I gallbladder carcinoma: is cholecystectomy alone adequate? HPB (Oxford). 2013;15(1):40–8.CrossRefGoogle Scholar
  18. 18.
    Ogura Y, Mizumoto R, Isaji S, et al. Radical operations for carcinoma of the gallbladder: present status in Japan. World J Surg. 1991;15(3):337–43.PubMedCrossRefGoogle Scholar
  19. 19.
    Goetze TO, Paolucci V. Benefits of reoperation of T2 and more advanced incidental gallbladder carcinoma. Ann Surg. 2008;247(1):104–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Prat F, Chapat O, Ducot B, et al. A randomized trial of endoscopic drainage methods for inoperable malignant strictures of the common bile duct. Gastrointest Endosc. 1998;47(1):1–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Schiffman SC, Metzger T, Dubel G, et al. Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival. Ann Surg Oncol. 2011;18(2):431–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Kuhlmann JB, Euringer W, Spangenberg HC, et al. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol. 2012;24(4):437–43.PubMedGoogle Scholar
  23. 23.
    Tse RV, Hawkins M, Lockwood G, et al. Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2008;25(4):657–64.CrossRefGoogle Scholar
  24. 24.
    Goodman KA, Wiegner EA, Maturen KE, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Rad Oncol Biol Phys. 2010;78(2):486–93.CrossRefGoogle Scholar
  25. 25.
    Barney BM, Olivier KR, Miller RC, et al. Clinical outcomes and toxicity using stereotactic body radiotherapy (SBRT) for advanced cholangiocarcinoma. Rad Oncol. 2012;7(67):1–7.Google Scholar
  26. 26.
    McMasters KM, Tuttle TM, Leach SD, et al. Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg. 1997;174(6):605–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Nelson JW, Ghafoori AP, Willett CG, et al. Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys. 2009;73(1):148–53.PubMedCrossRefGoogle Scholar
  28. 28.••
    Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30:1934–40. This study represents the largest pooled analysis of available data in the adjuvant therapy of biliary tract cancers and suggests a benefit from treatment. It is limited, however, by a wide range of therapies used over various decades with the potential for stage migration and selection bias.PubMedCrossRefGoogle Scholar
  29. 29.
    Kim S, Kim SW, Bang YJ, et al. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiation Oncology Biol Phys. 2002;54(2):414–9.CrossRefGoogle Scholar
  30. 30.•
    Neoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs. observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012;308(2):147–56. This is the largest prospective treatment of adjuvant therapy for periampullary cancers. Survival for the overall group was not improved with adjuvant therapy, but there did seem to be a benefit of adjuvant chemotherapy when controlling for independent prognostic variables.PubMedCrossRefGoogle Scholar
  31. 31.
    Bridgewater JA, Stubbs C, Primrose JN, National Cancer Research Institute (UK) Upper Gastrointestinal Studies Group: BILCAP. A randomized clinical trial evaluating adjuvant chemotherapy with capecitabine compared to expectant treatment alone following curative surgery for biliary tract cancer. J Clin Oncol. 2011;29(15_suppl):4125.Google Scholar
  32. 32.
    National Cancer Institute; UNICANCER. Gemcitabine hydrochloride and oxaliplatin or observation in treating patients with biliary tract cancer that has been removed by surgery. In: ClinicalTrials.gov[Internet]. Bethesda(MD): National Library of Medicine. 2000- [cited 2013 Apr 4]. Available from: http://clinicaltrials.gov/show/NCT01313377 NLM Identifier: NCT01313377.
  33. 33.
    Glimelius B, Hoffman K, Sjoden PO, et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996;7:593–600.PubMedCrossRefGoogle Scholar
  34. 34.
    Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer. 2007;96(6):896–902.PubMedCrossRefGoogle Scholar
  35. 35.
    Ychou M, Conroy T, Seitz JF, et al. An open phase I study assessing the feasibility of the triple combination: oxaliplatin plus irinotecan plus leucovorin/5-fluorouracil every 2 weeks in patients with advanced solid tumors. Ann Oncol. 2003;14(3):481–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Karachaliou N, Polyzos A, Kentepozidis N, et al. A multicenter phase II trial with irinotecan plus oxaliplatin as first-line treatment for inoperable/metastatic cancer of the biliary tract. Oncology. 2010;78(5–6):356–60.PubMedCrossRefGoogle Scholar
  37. 37.
    Feisthammel J, Schoppmeyer K, Mossner J, et al. Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas. Am J Clin Oncol. 2007;30(3):319–24.PubMedCrossRefGoogle Scholar
  38. 38.
    Chung MJ, Kim YJ, Park JY, et al. Prospective phase II trial of gemcitabine in combination with irinotecan as first-line chemotherapy in patients with advanced biliary tract cancer. Chemotherapy. 2011;57(3):236–43.PubMedCrossRefGoogle Scholar
  39. 39.••
    Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81. This large, prospective, phase 3 study demonstrated the superiority of cisplatin plus gemcitabine compared with gemcitabine alone and established cisplatin plus gemcitabine as the standard of care for the treatment of advanced biliary tract cancers. Moreover, the survival advantage seen with cisplatin plus gemcitabine was achieved without an increase in grade 3 or 4 toxicity.PubMedCrossRefGoogle Scholar
  40. 40.•
    Walter T, Horgan AM, McNamara M, et al. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study. Eur J Cancer. 2013;49(2):329–35. This is the largest retrospective study of second-line chemotherapy outcomes for patients with advanced biliary tract cancers and provides a context for moving forward in developing clinical trials to improve upon the 2.8-month median progression-free survival observed.PubMedCrossRefGoogle Scholar
  41. 41.
    Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological and prognostic significance of EGFR, VEGF and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98(2):418–25.PubMedCrossRefGoogle Scholar
  42. 42.
    Tannapfel A, Sommerer F, Benicke M, et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 2003;52(5):706–12.PubMedCrossRefGoogle Scholar
  43. 43.
    Yoon JH, Werneburg NW, Higuchi H, et al. Bile acids inhibit Mcl-1 protein turnover via an epidermal growth factor receptor/Raf-1-dependent mechanism. Cancer Res. 2002;62(22):6500–5.PubMedGoogle Scholar
  44. 44.
    El-Khoueiry AB, Rankin CJ, Ben-Josef E, et al. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs. 2012;30(4):1646–51.PubMedCrossRefGoogle Scholar
  45. 45.
    Bengala C, Bertolini F, Malavasi N, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer. 2010;102(1):68–72.PubMedCrossRefGoogle Scholar
  46. 46.
    Moehler MH, Schimanski CC, Kanzler S, et al.: A randomized, double-blind multicenter phase II AIO trial with gemcitabine plus sorafenib versus gemcitabine plus placebo in patients with chemotherapy-naïve advanced or metastatic biliary tract cancer: first safety and efficacy data. J Clin Oncol 2011, 29(suppl): Abstract 4077.Google Scholar
  47. 47.
    LoConte NK, Holen KD, Schelman WR, et al.: A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs 2012, epub ahead of print.Google Scholar
  48. 48.
    Yi J, Thongprasert S, Doval D, et al.: Phase II study of sunitinib as second-line treatment in advanced biliary tract carcinoma: multicenter, multinational study. J Clin Oncol 2011, 29(suppl): Abstract 14653.Google Scholar
  49. 49.
    Zhu AX, Meyerhardt JA, Blaszkowsky LS, et al. Efficacy and safety of gemcitabine, oxaliplatin and bevacizumab in advanced biliary tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol. 2010;11(1):48–54.PubMedCrossRefGoogle Scholar
  50. 50.
    Lubner SJ, Mahoney MR, Kolesar JL, et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol. 2010;28(21):3491–7.PubMedCrossRefGoogle Scholar
  51. 51.
    Nakazawa K, Dobashi Y, Suzuki S, et al. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers. J Pathol. 2005;206(3):356–65.PubMedCrossRefGoogle Scholar
  52. 52.
    Leone F, Cavalloni G, Pignochino Y, et al. Somatic mutations of epidermal growth factor receptor in bile duct and gallbladder carcinoma. Clin Cancer Res. 2006;12(6):1680–5.PubMedCrossRefGoogle Scholar
  53. 53.
    Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006;24(19):3069–74.PubMedCrossRefGoogle Scholar
  54. 54.
    Lee J, Park SH, Chang HM, et al. Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicenter, open-label, randomized phase 3 study. Lancet Oncol. 2012;13(2):181–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Ciombor KK, Cardin DB, Chan E, et al.: Phase Ib study of gemcitabine and oxaliplatin with erlotinib in patients with advanced biliary tract cancer. J Clin Oncol 2012, 30(suppl): Abstract 14503.Google Scholar
  56. 56.
    Gruenberger B, Schueller J, Heubrandtner U, et al. Cetuximab, gemcitabine and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol. 2010;11(12):1142–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Malka D, Fartoux L, Rousseau V, et al.: Gemcitabine and oxaliplatin (GEMOX) alone or in combination with cetuximab as first-line treatment for advanced biliary cancer: final analysis of a randomized phase II trial (BINGO). J Clin Oncol 2012, 30(suppl): Abstract 4032.Google Scholar
  58. 58.
    Zhang Z, Oyesanya RA, Campbell DJ, et al. Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy. Hepatology. 2010;52(3):975–86.PubMedCrossRefGoogle Scholar
  59. 59.
    Peck J, Wei L, Zalupski M, et al. HER2/neu may not be an interesting target in biliary cancers: results of an early phase II study with lapatinib. Oncology. 2012;82(3):175–9.PubMedCrossRefGoogle Scholar
  60. 60.
    Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol. 2009;64(4):777–83.PubMedCrossRefGoogle Scholar
  61. 61.•
    Bekaii-Saab T, Phelps MA, Li X, et al. Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol. 2011;29(17):2357–63. This study demonstrated a signal for the efficacy of MEK inhibition in biliary cancers and the rationale for further investigation in this pathway.PubMedCrossRefGoogle Scholar
  62. 62.
    National Cancer Institute; University College, London. ABC-04 a study of cisplatin, gemcitabine and selumetinib in patients with advanced biliary tract cancer. In: ClinicalTrials.gov[Internet]. Bethesda(MD): National Library of Medicine. 2000- [cited 2013 Apr 4]. Available from: http://clinicaltrials.gov/show/NCT01242605 NLM Identifier: NCT01242605.
  63. 63.
    Xu J, Knox JJ, Ibrahimov E, et al. Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer. Clin Cancer Res. 2013;19(1):118–27.PubMedCrossRefGoogle Scholar
  64. 64.
    Kaida M, Morita-Hoshi Y, Soeda A, et al. Phase 1 trial of Wilms tumor 1 (WT1) peptide vaccine and gemcitabine combination therapy in patients with advanced pancreatic or biliary tract cancer. J Immunother. 2011;34(1):92–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Okusaka T, Ueno M, Sato T, et al. Possibility of immunotherapy for biliary tract cancer: how do we prove efficacy? Introduction to a current ongoing phase I and randomized phase II study to evaluate the efficacy and safety of adding Wilms tumor 1 peptide vaccine to gemcitabine and cisplatin for the treatment of advanced biliary tract cancer (WT-BT trial). J Hepatobiliary Pancreat Sci. 2012;19(4):314–8.PubMedCrossRefGoogle Scholar
  66. 66.
    Voss JS, Holtegaard LM, Kerr SE, et al.: Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions. Hum Pathol 2013, epub ahead of print.Google Scholar
  67. 67.
    Deshpande V, Nduaguba A, Zimmerman SM, et al. Mutational profiling reveals PIK3CA mutations in gallbladder carcinoma. BMC Cancer. 2011;11:60.PubMedCrossRefGoogle Scholar
  68. 68.
    Borger DR, Tanabe KK, Fan KC, et al. Frequent mutation of isocitrate dehydrogenase (IDH) 1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2012;17(1):72–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Gu TL, Deng X, Huang F, et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One. 2011;6(1):e15640.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.NashvilleUSA

Personalised recommendations